West Paces Advisors’s CASI Pharmaceuticals CASI Stock Holding History

West Paces Advisors’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11	Hold	100	–	–	﹤0.01%	690
2026 Q2	$17	Buy	+100	New	+$17	﹤0.01%	765
2025 Q2	–	Sell	-100	Closed	-$216	–	263
2025 Q1	$216	Hold	100	–	–	﹤0.01%	549
2024 Q4	$283	Hold	100	–	–	﹤0.01%	538
2024 Q3	$616	Hold	100	–	–	﹤0.01%	507
2024 Q2	$550	Hold	100	–	–	﹤0.01%	528
2024 Q1	$361	Hold	100	–	–	﹤0.01%	558
2023 Q4	$716	Hold	100	–	–	﹤0.01%	530
2023 Q3	$256	Hold	100	–	–	﹤0.01%	509
2023 Q2	$250	Hold	100	–	–	﹤0.01%	535
2023 Q1	$232	Hold	100	–	–	﹤0.01%	547
2022 Q4	$179	Buy	+100	New	+$198	﹤0.01%	525

West Paces Advisors's CASI Position: Q3 2026 in Review

West Paces Advisors held its CASI Pharmaceuticals (CASI) position steady in Q3 2026 at 100 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #690.

West Paces Advisors first reported a position in CASI in Q4 2022 and has held it in 12 quarters since. The position peaked at $716 in Q4 2023. 1 fund tracked by Wall St. Rank holds CASI as of Q3 2026.

West Paces Advisors held 100 shares of CASI Pharmaceuticals worth $11 as of Q3 2026.
West Paces Advisors left its CASI Pharmaceuticals share count unchanged in Q3 2026.
CASI Pharmaceuticals made up ﹤0.01% of West Paces Advisors's portfolio in Q3 2026, its #690 holding.
West Paces Advisors first reported a position in CASI Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
West Paces Advisors's CASI Pharmaceuticals position peaked at $716 in Q4 2023.
1 fund tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2026.

Based on West Paces Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.